Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tars and anthralins

A Silverman1, A Menter, J L Hairston

  • 1Baylor Psoriasis Center, Dallas, TX 75246, USA.

Dermatologic Clinics
|October 1, 1995
PubMed
Summary
This summary is machine-generated.

This review discusses the pharmacology and historical use of tar and anthralin for psoriasis. It examines traditional and modern treatment approaches, offering guidance on their therapeutic application.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1).

The British journal of dermatology·2020
Same author

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study.

The British journal of dermatology·2020
Same author

Defining drug-free remission of skin disease in patients with plaque psoriasis.

The British journal of dermatology·2019
Same author

Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same journal

The Evidence Is In: Devices and Biologics Reshaping Modern Dermatology.

Dermatologic clinics·2026
Same journal

Energy-Based Devices for Body Contouring.

Dermatologic clinics·2026
Same journal

Microfocused Ultrasound with Visualization for Skin Tightening: Clinical Applications, Safety, and Technical Considerations.

Dermatologic clinics·2026
Same journal

Devices in Onychomycosis: A Status Update.

Dermatologic clinics·2026
Same journal

Acne Laser Devices in Dermatology.

Dermatologic clinics·2026
Same journal

Fractional Laser Therapy for Androgenetic Alopecia: Mechanisms, Clinical Evidence, and Practical Implementation.

Dermatologic clinics·2026
See all related articles

Area of Science:

  • Dermatology
  • Pharmacology
  • Medical History

Background:

  • Coal tar and anthralin are established topical treatments for psoriasis.
  • Traditional regimens like Goeckerman and Ingram have been foundational in psoriasis management.
  • Psoriasis treatment has evolved with newer therapeutic options.

Purpose of the Study:

  • To review the pharmacology and mechanisms of action of tar and anthralin.
  • To provide historical context for these psoriasis therapies.
  • To offer recommendations for current therapeutic use.

Main Methods:

  • Literature review of pharmacology, historical use, and clinical studies.
  • Analysis of traditional and contemporary psoriasis treatment regimens.
  • Synthesis of evidence for monotherapy and adjunctive use.

Related Experiment Videos

Main Results:

  • Detailed discussion of tar and anthralin pharmacology and mechanisms.
  • Historical perspective on the evolution of psoriasis treatment.
  • Evidence-based recommendations for clinical application.

Conclusions:

  • Tar and anthralin remain relevant in psoriasis management.
  • Understanding their properties informs optimal therapeutic strategies.
  • These agents can be used effectively as monotherapy or adjuncts.